Dr. Soliman on Investigational Combination Therapies in Patients With Breast Cancer

Hatem Soliman, MD
Published: Monday, Apr 30, 2018



Hatem Soliman, MD, medical oncologist, The Center for Women’s Oncology, Moffitt Cancer Center, discusses the use of combination therapies in the treatment of patients with breast cancer.

Immunotherapy agents, specifically checkpoint inhibitors, has received the most focus because that is where the most development has occurred. These agents have been run through early phase trials, and some of these agents are in phase III registration studies as well, states Soliman.

Physicians also want to look at future combinations and strategies using other checkpoint inhibitors or immunomodulatory drugs, such as LAG-3 agents, which appear to be showing some potential promise in combination with other checkpoint treatments. The use of oncolytic therapy is also being explored in a clinical trial at Moffitt Cancer Center, says Soliman.
 


Hatem Soliman, MD, medical oncologist, The Center for Women’s Oncology, Moffitt Cancer Center, discusses the use of combination therapies in the treatment of patients with breast cancer.

Immunotherapy agents, specifically checkpoint inhibitors, has received the most focus because that is where the most development has occurred. These agents have been run through early phase trials, and some of these agents are in phase III registration studies as well, states Soliman.

Physicians also want to look at future combinations and strategies using other checkpoint inhibitors or immunomodulatory drugs, such as LAG-3 agents, which appear to be showing some potential promise in combination with other checkpoint treatments. The use of oncolytic therapy is also being explored in a clinical trial at Moffitt Cancer Center, says Soliman.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x